LCP
TECH icon

Legacy Capital Partners’s Bio-Techne TECH Stock Holding History

Legacy Capital Partners’s Portfolio TECH Stock Details TECH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,660
Closed -$215K – 144
2021
Q4 		$215K Hold
1,660
– – 0.07% 137
2021
Q3 		$201K Buy
+1,660
New +$202K 0.07% 132

Other funds holding TECH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

Legacy Capital Partners's TECH Position: Q1 2022 in Review

Legacy Capital Partners sold out of Bio-Techne (TECH) in Q1 2022, closing a stake of 1,660 shares — an estimated $215K sold.

Legacy Capital Partners first reported a position in TECH in Q3 2021 and held it in 2 quarters. The position peaked at $215K in Q4 2021. 556 funds tracked by Wall St. Rank hold TECH as of Q1 2022.

  • Legacy Capital Partners reported no remaining Bio-Techne position as of Q1 2022 after selling out during the quarter.
  • Legacy Capital Partners sold 1,660 Bio-Techne shares in Q1 2022, an estimated $215K.
  • Legacy Capital Partners first reported a position in Bio-Techne in Q3 2021 and held it in 2 quarters.
  • Legacy Capital Partners's Bio-Techne position peaked at $215K in Q4 2021.
  • 556 funds tracked by Wall St. Rank held Bio-Techne as of Q1 2022.

Based on Legacy Capital Partners's 13F filing for Q1 2022, filed 11 Apr 2022.